NET PROFIT FORECAST: Takeda is expected to post a 59% drop in net profit to 43.58 billion yen, equivalent to $280.2 million, for the three months ended Dec. 31, according to a poll of analysts by data ...
Request To Download Free Sample of This Strategic Report@ Highlighted with 59 tables and 54 figures, this 141-page report ?Asia Pacific Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, ...
Request To Download Free Sample of This Strategic Report @ Highlighted with 52 tables and 51 figures, this 132-page report ?North America Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease ...
USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...
Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...
TipRanks on MSN1d
Neurocrine Amends License Agreement with TakedaAn announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...
Ballentine Partners LLC grew its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 24.3% in the 4th quarter, according to the company in its most recent filing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback